Ichikawa, T.; Suekane, A.; Nakahata, S.; Iha, H.; Shimoda, K.; Murakami, T.; Morishita, K.
Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma. Int. J. Mol. Sci. 2024, 25, 2842.
https://doi.org/10.3390/ijms25052842
AMA Style
Ichikawa T, Suekane A, Nakahata S, Iha H, Shimoda K, Murakami T, Morishita K.
Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma. International Journal of Molecular Sciences. 2024; 25(5):2842.
https://doi.org/10.3390/ijms25052842
Chicago/Turabian Style
Ichikawa, Tomonaga, Akira Suekane, Shingo Nakahata, Hidekatsu Iha, Kazuya Shimoda, Takashi Murakami, and Kazuhiro Morishita.
2024. "Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma" International Journal of Molecular Sciences 25, no. 5: 2842.
https://doi.org/10.3390/ijms25052842
APA Style
Ichikawa, T., Suekane, A., Nakahata, S., Iha, H., Shimoda, K., Murakami, T., & Morishita, K.
(2024). Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma. International Journal of Molecular Sciences, 25(5), 2842.
https://doi.org/10.3390/ijms25052842